6月5日，睿智医药今日收盘10.16元，下跌3.05%，最新市净率4.15，总市值50.59亿元。 资金流向方面，6月5日，睿智医药主力资金净流出8383.88万元，近5日总体呈流出状态，5日共流出 15698.18万元。 最新一期业绩显示，2025年一季报，公司实现营业收入2.61亿元，同比11.37%；净利润664.21万元，同 比126.09%，销售毛利率27.44%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)11睿智医药-26.03-22.344.1550.59亿行业平均 40.8246.973.46158.62亿行业中值45.9353.092.7358.93亿1润达医疗-291.25192.732.51106.54亿2何氏眼 科-154.63-134.561.9336.87亿3*ST生物-126.41-122.8910.3824.39亿4诚达药业-72.40-124.031.6334.86亿5普 瑞眼科-66.27-59.532.8460.64亿6皓宸医疗-52.62-63.296.2423.86亿7创新医疗-47.91-53.502.8550.26亿8国际 医学-44.81-45.0 ...

Group 1: Financial Performance - In Q1 2025, the company achieved revenue of 3.099 billion CNY, a year-on-year increase of 16% [2] - The net profit attributable to shareholders was 306 million CNY, reflecting a growth of 32.5% year-on-year [2] - Adjusted net profit was 349 million CNY, with a year-on-year growth rate of 3.1%, which is slower than revenue growth [2] Group 2: Business Segment Performance - Laboratory services generated revenue of 1.857 billion CNY, up 15.7% year-on-year, with a gross margin of 45.5%, an increase of 1.4 percentage points [4] - CMC (small molecule CDMO) services reported revenue of 693 million CNY, a growth of 19.1%, with a gross margin of 30.4%, up 2.5 percentage points [4] - Clinical research services achieved revenue of 447 million CNY, marking a 14.2% increase [4] - Revenue from large molecule and cell & gene therapy services was 99 million CNY, reflecting a growth of 7.9% [4] Group 3: Operational Insights - The strong operating cash flow reached 853 million CNY, a year-on-year increase [2] - The company’s workforce increased compared to the same period in 2024 due to new hires [2] - The second phase of the small molecule CDMO in Shaoxing is under construction, with two workshops expected to be operational by the end of 2025 [6] Group 4: Market Dynamics - Over 90% of the small molecule CDMO business comes from overseas clients, indicating a strong international market presence [7] - The company’s laboratory chemical services are expanding in scope, driven by industry recovery and new technology developments [5]